Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth...
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.
argenx (NASDAQ:ARGX) reported first-quarter 2026 results highlighting continued commercial growth for VYVGART and progress across multiple late-stage pipeline programs, while newly appointed CEO Karen...
Barchart Research What to Expect from ARGX Earnings ARGX Generated May 6, 2026 Current Price $807.55 EPS Estimate $$5.16 Consensus Rating Strong Buy Average Move 4.81% Argenx Reports Tomorrow With Analysts...
TORONTO , Nov. 5, 2025 /CNW/ - argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Microbot Medical (MBOT – Research Report), Argenx Se (ARGX – Research Report) and AnaptysBio (ANAB –...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...
In a report released today, Yaron Werber from TD Cowen reiterated a Buy rating on Argenx Se, with a price target of $800.00. The company’s shares closed yesterday at $812.95.Elevate Your Investing Strategy:...
Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Argenx Se yesterday and set a price target of $775.00. The company’s shares closed yesterday at $799.56.Elevate Your Investing Strategy:...
In a report released on October 8, Luca Issi from RBC Capital maintained a Buy rating on Argenx Se. The company’s shares closed yesterday at $804.90.Elevate Your Investing Strategy: Take advantage of...